<div id="readability-page-1">Key Takeaways Abbott Laboratories has agreed to acquire Exact Sciences Corp. in a deal worth $21 billion, paying shareholders $105 per share.Exact Sciences makes a variety of cancer screening tests, including Cologuard, and expects to generate about $3 billion in revenue this year.Many pharmaceutical companies are spending billions to develop scree...</div>

EXAS

<p>Abbott Laboratories has agreed to acquire Exact Sciences Corp. for $21 billion, paying shareholders $105 per share. Exact Sciences, known for its cancer screening tests like Cologuard, expects to generate about $3 billion in revenue this year. This acquisition is part of a broader trend of pharmaceutical companies investing heavily in cancer screening development.</p>

Why the Stock Price of This Cancer Screening Company Soared 17% Thursday